Eli Lilly’s growth driver, tirzepatide, under scrutiny from investors, while oral GLP-1 candidate faces key phase 3 results in weight management. Shares may seem expensive, but justified by Lilly’s prospects. Critical areas to watch: sales growth and potential label expansions for tirzepatide. Lilly’s stock faces high standards with upcoming results.

Lilly’s revenue grew by 45% year over year to $12.7 billion, but guidance disappointment led to share price drop. Second-quarter results due on Aug. 7 could impact stock price. Despite potential catalysts, Lilly’s innovative abilities and strong pipeline make a strong case for the stock.

Lilly’s forward price-to-earnings ratio is 35.5, reflecting high expectations. The company has been growing revenue faster than industry peers, justifying the premium. As a dividend stock, Lilly is attractive for income-seeking investors. Shares slightly lagged the S&P 500, making Eli Lilly a buy at current levels.

Read more at Yahoo Finance: The 3 Things That Matter for Eli Lilly Now